Sitilo experience on peritoneal carcinomatosis from colorectal cancer: clinical prognostic features

J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):29-33.

Abstract

A multicentric prospective study has been carried on 69 patients affected by peritoneal carcinomatosis from colorectal cancer. Patients have been treated by cytoreductive surgery and intraoperative hyperthermic chemoperfusion. CC 0-1 has been achieved in 82%. Major morbidity and mortality was 21.7% and 2.9% respectively. Three-yrs overall survival was 26.7% for all series. Difference in survival evaluating CC 0-1 vs. CC 2 pts and PCI < or = 10 vs. >10 was statistically significant. Evaluating only patients CC 0-1 and PCI < or = 10 4-yrs overall survival rised up to 44.7%. A smaller subgroup of patients with a disease-free interval to peritoneal carcinomatosis > or = 2-yrs showed a 5-yrs disease-free survival of 50%.

Conclusions: PCI < or = 10, complete or optimal cytoreduction feasibility have to be considered for the patients selection to the integrate treatment. Disease-free interval seems to be a powerful prognostic indicator and deserve to be better outlined in further studies.

Publication types

  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Chemotherapy, Cancer, Regional Perfusion
  • Cisplatin / administration & dosage
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology*
  • Colorectal Neoplasms / therapy*
  • Combined Modality Therapy
  • Digestive System Surgical Procedures
  • Disease-Free Survival
  • Humans
  • Hyperthermia, Induced
  • Middle Aged
  • Mitomycin / administration & dosage
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / secondary*
  • Peritoneal Neoplasms / therapy*
  • Prognosis
  • Societies, Medical
  • Survival Analysis
  • Treatment Outcome

Substances

  • Mitomycin
  • Cisplatin